04:28:09 Europe / Stockholm

Prenumeration

Filter arrow-icon
Språk arrow-icon
2023-06-28 11:05:00
Magle Group initiates collaboration with leading German university hospital to explore synergies between EmboCept® S DSM 50 µm and immunotherapies
Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) today announces that the company has established a collaboration with Charité – Universitätsmedizin Berlin to evaluate the combination of its vascular embolic agent EmboCept® S DSM 50 µm and immunotherapy
2023-05-16 11:00:00
Magle Group broadens its project portfolio through in-licensing of clinical-stage cancer vaccine candidate from CHOSA Oncology AB
Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) today announces that the company has in-licensed the clinical-stage therapeutic cancer vaccine candidate onilcamotide from Chosa Oncology AB. Magle Group plans to further develop onilcamotide by use of its proprietary degradable starch microspheres (DSM) technology. The company sees a future potential to combine onilcamotide treatment...
2021-02-27 10:01:00
Magle Chemoswed congratulates Oncopeptides
Magle Chemoswed congratulates everyone at Oncopeptides for receiving FDA approval of PEPAXTO®. We are proud to have been chosen by Oncopeptides as a development and manufacturing partner for the active pharmaceutical substance. It has been a great pleasure to support Oncopeptides and supply development and manufacturing services around the active pharmaceutical substance through all phases of the...
2020-07-07 09:45:00
Encapsulation of pharmaceutical proteins in starch microparticles project
Magle Chemoswed joins collaboration with Malmö University on exciting new project. The project will focus on the use of the Company technology platform as a novel delivery system in conjunction with proteins. Protein-based therapeutics are becoming increasingly popular in medicine. Compared to low molecular drugs, they are more specific, cause fewer side effects and are environmentally friendly. ...